BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 27346339)

  • 1. Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1ng/ml following prostatectomy: How much information can conventional imaging provide?
    Vargas HA; Martin-Malburet AG; Takeda T; Corradi RB; Eastham J; Wibmer A; Sala E; Zelefsky MJ; Weber WA; Hricak H
    Urol Oncol; 2016 Nov; 34(11):482.e5-482.e10. PubMed ID: 27346339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (11)C-choline PET/CT and multiparametric MRI in patients with biochemical relapse of prostate cancer.
    Garcia JR; Romera N; Cozar M; Soler M; Moragas M; Escobar M
    Actas Urol Esp; 2015 May; 39(4):259-63. PubMed ID: 25454265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of
    García JR; Compte A; Buxeda M; Mourelo S; Soler M; Blanch A; Valls E; Riera E
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(4):197-203. PubMed ID: 32165153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer].
    García JR; Soler M; Blanch MA; Ramírez I; Riera E; Lozano P; Pérez X; Delgado E; Carrio I; Lomeña F
    Rev Esp Med Nucl; 2009; 28(3):95-100. PubMed ID: 19558948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse.
    Oyama N; Miller TR; Dehdashti F; Siegel BA; Fischer KC; Michalski JM; Kibel AS; Andriole GL; Picus J; Welch MJ
    J Nucl Med; 2003 Apr; 44(4):549-55. PubMed ID: 12679398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Single center experience of (18F)-fluorocholine positron emission tomography: analysis of its impact on salvage local therapy in patients with prostate adenocarcinoma].
    Moussaid Y; Bonardel G; Jacob J; Métivier D; Gontier E; Bauduceau O; Durand X; Fayolle M; Houlgatte A; Foehrenbach H; Védrine L; Chargari C
    Cancer Radiother; 2013; 17(4):259-64. PubMed ID: 23702489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?
    Goldstein J; Even-Sapir E; Ben-Haim S; Saad A; Spieler B; Davidson T; Berger R; Weiss I; Appel S; Lawrence YR; Symon Z
    Am J Clin Oncol; 2017 Jun; 40(3):256-259. PubMed ID: 25319322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic utility and therapeutic impact of PET/CT [
    Sánchez N; Valduvieco I; Ribal MJ; Campos F; Casas F; Nicolau C; Salvador R; Mellado B; Jorcano S; Fuster D; Paredes P
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(5):284-291. PubMed ID: 32467000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy.
    Schöder H; Herrmann K; Gönen M; Hricak H; Eberhard S; Scardino P; Scher HI; Larson SM
    Clin Cancer Res; 2005 Jul; 11(13):4761-9. PubMed ID: 16000572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (18)F-choline PET/CT for early detection of metastases in biochemical recurrence following radical prostatectomy.
    Kjölhede H; Ahlgren G; Almquist H; Liedberg F; Lyttkens K; Ohlsson T; Bratt O
    World J Urol; 2015 Nov; 33(11):1749-52. PubMed ID: 25824540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of Recurrence, Detection Rates, and Impact of 18-F Fluciclovine PET/CT on the Management of Men With Recurrent Prostate Cancer.
    Michael J; Khandani AH; Basak R; Tan HJ; Royce TJ; Wallen E; Whang Y; Rose TL; Milowsky M; Bjurlin MA
    Urology; 2021 Sep; 155():192-198. PubMed ID: 33516829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Whole Body and Multiparametric Prostate Magnetic Resonance Imaging as a 1-Step Approach to the Simultaneous Assessment of Local Recurrence and Metastatic Disease after Radical Prostatectomy.
    Robertson NL; Sala E; Benz M; Landa J; Scardino P; Scher HI; Hricak H; Vargas HA
    J Urol; 2017 Jul; 198(1):65-70. PubMed ID: 28216327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Impact of 68Ga-PSMA PET/CT in a Patient With Biochemical Recurrence of Prostate Cancer.
    Queiroz MA; Viana P; Santos A; Bastos D; Etchebehere E; Cerri G
    Clin Nucl Med; 2016 Sep; 41(9):e417-9. PubMed ID: 27276202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy.
    Vees H; Buchegger F; Albrecht S; Khan H; Husarik D; Zaidi H; Soloviev D; Hany TF; Miralbell R
    BJU Int; 2007 Jun; 99(6):1415-20. PubMed ID: 17428249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significant increase in detection of prostate cancer recurrence following radical prostatectomy with an early imaging acquisition protocol with ¹⁸F-fluorocholine positron emission tomography/computed tomography.
    Simone G; Di Pierro GB; Papalia R; Sciuto R; Rea S; Ferriero M; Guaglianone S; Maini CL; Gallucci M
    World J Urol; 2015 Oct; 33(10):1511-8. PubMed ID: 25577130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of tumor recurrences after radical prostatectomy using 18F-Choline PET/CT and 3T multiparametric MRI without endorectal coil: a single center experience.
    Couñago F; Recio M; Maldonado A; Del Cerro E; Díaz-Gavela AA; Thuissard IJ; Sanz-Rosa D; Marcos FJ; Olaciregui K; Mateo M; Cerezo L
    Cancer Imaging; 2016 Dec; 16(1):42. PubMed ID: 27927229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Multimodality MRI and PET for restaging prostate cancer after biochemical failure of the treatment].
    Cochet A; Kanoun S; Humbert O; Walker PM; Cormier L; Créhange G; Brunotte F
    Cancer Radiother; 2014 Oct; 18(5-6):509-16. PubMed ID: 25195114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment.
    Chen B; Bathala TK; Xu G; Teyateeti A; Chapin BF; Tang C; Tu SM; Macapinlac HA; Lu Y
    Clin Nucl Med; 2020 May; 45(5):349-355. PubMed ID: 31977495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer.
    Nagda SN; Mohideen N; Lo SS; Khan U; Dillehay G; Wagner R; Campbell S; Flanigan R
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):834-40. PubMed ID: 17293236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil.
    Kitajima K; Murphy RC; Nathan MA; Froemming AT; Hagen CE; Takahashi N; Kawashima A
    J Nucl Med; 2014 Feb; 55(2):223-32. PubMed ID: 24434294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.